Evidence map›Paper›PMID 37446626›Full record

ArticleMolecules (Basel, Switzerland)2023

Design, Synthesis, Molecular Docking Study and Biological Evaluation of Novel γ-Carboline Derivatives of Latrepirdine (Dimebon) as Potent Anticancer Agents.

Ramakrishna Voggu, Arundhati Karmakar, Venkat Swamy Puli, V Surendra Babu Damerla, Padma Mogili, P Amaladass, Sridhar Chidara, Kalyan Kumar Pasunooti, Sarika Gupta

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ramakrishna VogguDepartment of Medicinal Chemistry, Aragen Life Sciences Pvt. Ltd. (Formerly Known as GVK Biosciences Pvt. Ltd.), IDA, Nacharam, Hyderabad 500076, Telangana, India.
Arundhati KarmakarMolecular Science Laboratory, National Institute of Immunology, New Delhi 110067, India.
Venkat Swamy PuliDepartment of Medicinal Chemistry, Aragen Life Sciences Pvt. Ltd. (Formerly Known as GVK Biosciences Pvt. Ltd.), IDA, Nacharam, Hyderabad 500076, Telangana, India.
V Surendra Babu DamerlaDepartment of Medicinal Chemistry, Aragen Life Sciences Pvt. Ltd. (Formerly Known as GVK Biosciences Pvt. Ltd.), IDA, Nacharam, Hyderabad 500076, Telangana, India.
Padma MogiliDepartment of Engineering Chemistry, Andhra University, Visakhapatnam 530003, Andhra Pradesh, India.
P AmaladassDepartment of Chemistry, Madanapalle Institute of Technology & Science, Madanapalle 517325, Andhra Pradesh, India.
Sridhar ChidaraDepartment of Medicinal Chemistry, Aragen Life Sciences Pvt. Ltd. (Formerly Known as GVK Biosciences Pvt. Ltd.), IDA, Nacharam, Hyderabad 500076, Telangana, India.
Kalyan Kumar PasunootiProSAM Bioscience Pvt. Ltd., Hyderabad 500049, Telangana, India.ORCID 0000-0002-6039-0122
Sarika GuptaMolecular Science Laboratory, National Institute of Immunology, New Delhi 110067, India.
Andhra University · INNational Institute of Immunology · INJohns Hopkins University · US

Funding

Department of biotechnology NII core
6 · The paper itself

Abstract

A series of novel γ-Carboline derivatives were designed and synthesized using the Suzuki coupling reaction to identify the leads for the activity against cancer. Interestingly, these compounds were tested for their anticancer activity against the cell lines, particularly human cancer cell lines MCF7 (breast), A549 (lung), SiHa (cervix), and Colo-205 (colon). Most of the γ-Carboline derivatives showed potent inhibitory activity in four cancer cell lines, according to in vitro anticancer activity screening. Two compounds, specifically

Indexed as

Antineoplastic AgentsCarbolinesCell Line, TumorCell ProliferationDrug DesignDrug Screening Assays, AntitumorEtoposideFemaleHumansIndolesMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsCarbolinesEtoposidegamma-carbolineIndoleslatrepirdineanticancer activitycancer cell lineLatrepirdine (Dimebon)molecular dockingstructure-activity relationshipγ-Carboline

Identifiers

PMID37446626
PMCPMC10343707
OpenAlexW4382134840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.